Article (Published version) (1.8 MB) - Limited access to UNIGE
BORA-dependent PLK1 regulation: A new weapon for cancer therapy?
|Published in||Molecular & Cellular Oncology. 2016, vol. 3, no. 5, p. e1199265|
|Abstract||The mitotic kinase polo like kinase 1 (PLK1) is overexpressed in many cancers and its inhibition slows down proliferation and increases apoptosis in cancer cell lines. Understanding how PLK1 is activated is therefore crucial for the development of novel PLK1 inhibitors with anticancer properties. We recently identified a conserved regulatory loop leading to PLK1 activation that involves cyclin-dependent kinase 1 (CDK1).|
|Research group||La division asymétrique (847)|
|CIRILLO, Luca et al. BORA-dependent PLK1 regulation: A new weapon for cancer therapy?. In: Molecular & Cellular Oncology, 2016, vol. 3, n° 5, p. e1199265. https://archive-ouverte.unige.ch/unige:111961|